Renzenbrink & Partner advises Klingel medical metal on the acquisition of Ruetschi Group

23 November 2021

Renzenbrink & Partner has advised Klingel-medical metal group (“Klingel medical metal”), a portfolio company of IK VIII Fund (“IK”), on the acquisition of Ruetschi Technology Holding AG (“Ruetschi”). Ruetschi is a leading Swiss full service provider of sterile packaged single-use medical devices with a special focus on orthopaedics and spinal surgery. Based in Muntelier, Switzerland, the MedTech group companies forming Ruetschi operate additional facilities in Yverdon-les-Bains (Switzerland) and Renquishausen (Germany) and employ more than 200 employees.

By the acquisition of Ruetschi, Klingel medical metal with more than 600 employees worldwide, adds further manufacturing capabilities and leading MedTech customers to its established platform in Switzerland.

Renzenbrink & Partner had advised IK in 2018 on the acquisition of Klingel medical metal and subsequently acted as lead legal advisor on two add-on acquisitions in Switzerland (Gehring Cut AG and Bächler Feintech AG) as well as one German add-on (Puracon GmbH).

With regard to the acquisition of Ruetschi, Renzenbrink & Partner acted as lead advisor and advised on all German corporate and tax aspects of the transaction (including a reinvestment) with a team consisting of partners Dr Niels Maier, Dr Ulf Renzenbrink (both Corporate/PE) and Marc H. Kotyrba (Tax/PE) as well as counsel Christopher Blumenthal and associates Dr Alexander Haunschild (both Corporate/PE) and Marie Eikmeier (Tax/PE). Wenger & Vieli AG advised on all Swiss corporate and tax aspects of the transaction.